Drugs / Caspofungin
Caspofungin
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | CANCIDAS | — | 2002-09-20 – 2009-06-26 | fda.gov ↗ |
| Approved | EU (EMA) | Cancidas (previously Caspofungin MSD) | — | 2001-10-23 | europa.eu ↗ |
| Approved | US (FDA) | CANCIDAS | — | 2001-01-26 | fda.gov ↗ |
Trials 50
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06892951 | Dec 2025 → Dec 2026 expected | pneumocystosis | University Hospital, Tours | Recruiting | No outcome recorded |
| Phase 221 trials | ||||||
| Phase 2 | NCT03857399 | Sep 2018 → Dec 2019 | fungal infectious disease | Cttq | Completed | No outcome recorded |
| Phase 2 | NCT01945281 | Jan 2014 → Jan 2018 | candidiasis, invasive | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02941068 | Mar 2012 → Jun 2016 | intestinal perforation | Nanjing PLA General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01501708 | Dec 2011 → Jun 2017 | disease related to hematopoietic stem cell transplant, leukemia | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT01318148 | Apr 2011 → Sep 2013 | fungal infectious disease | Werner J. Heinz | Completed | No outcome recorded |
| Phase 2 | NCT01045798 | Dec 2010 → Apr 2012 | candidiasis, invasive | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01165320 | Jul 2010 → Sep 2013 | aspergillosis, candidiasis, invasive, esophageal candidiasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01260974 | May 2009 → Nov 2012 | fungal infectious disease | Azienda Ospedaliera di Padova | Unknown | No outcome recorded |
| Phase 2 | NCT00501098 | Jan 2007 → Dec 2008 | invasive aspergillosis | Northern Italy Leukemia Group | Completed | No outcome recorded |
| Phase 2 | NCT00404092 | Oct 2006 → Oct 2009 | invasive aspergillosis | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT00330395 | May → Oct 2006 | candidiasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00110045 | Feb 2005 → Mar 2008 | cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT00083343 | May 2004 → Feb 2006 | candidiasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00292071 | May 2004 → Jul 2006 | fungal infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00148148 | May 2004 → Dec 2007 | disease related to hematopoietic stem cell transplant, fungal infectious disease | University Hospital Muenster | Completed | No outcome recorded |
| Phase 2 | NCT00082524 | Apr 2004 → Jul 2007 | aspergillosis, candidiasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00082537 | Apr 2004 → Oct 2006 | neutropenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00333645 | Oct 2003 → Mar 2007 | fungal infectious disease | Grupo de Estudio de Infecciones en Transplantados | Unknown | No outcome recorded |
| Phase 2 | NCT00238355 | Aug 2003 → Jun 2008 | cancer of unknown primary site, infectious disease | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00076869 | Jan 2003 → Sep 2004 | invasive aspergillosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00005920 | — | HIV infectious disease, oral candidiasis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00748345 | Feb 2009 → Feb 2010 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 314 trials · 2 met primary · 3 missed | ||||||
| Phase 3 | NCT03580733 | Jan 2019 → Oct 2024 overdue | candidiasis | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT01503515 | Mar 2013 → Dec 2019 | fungal infectious disease, hematopoietic and lymphoid cell neoplasm | Children's Oncology Group | Completed | Missed primary |
| Phase 3 | NCT01288378 | Mar 2012 → Apr 2019 | fungal infectious disease, leukemia, myelodysplastic syndrome | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Met primary |
| Phase 3 | NCT01307579 | Apr 2011 → Jun 2018 | acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation, acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent, acute myeloid leukemia with minimal differentiation +9 | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00806351 | Aug 2009 → Oct 2011 | candidiasis, neutropenia | Pfizer | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT00805740 | Apr 2009 → Jun 2012 | candidiasis | Pfizer | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT00717860 | Aug 2008 → Jul 2010 | fungal infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00635648 | Jan 2008 → May 2011 | fungal infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00548080 | Mar → Nov 2006 | fungal infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00250432 | Jan 2006 → Jan 2008 | candidiasis, invasive | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00379964 | Jun 2005 → May 2006 | fungal infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00099775 | Dec 2004 → Sep 2005 | candidiasis | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00095316 | Oct 2004 → Sep 2006 | candidiasis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 3 | NCT00008359 | Aug 2000 → Mar 2003 | cancer | Memorial Sloan Kettering Cancer Center | Completed | Met primary |
| Phase 48 trials | ||||||
| Phase 4 | NCT07788586 | Sep 2026 → Feb 2028 expected | candidemia | Oliver Cornely, MD | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03978559 | Aug 2019 → Jun 2022 | pneumocystosis | Bin Du | Unknown | No outcome recorded |
| Phase 4 | NCT02805049 | Jan 2017 → Jun 2018 | infectious disease with sepsis, peritonitis | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01994096 | Nov 2013 → Oct 2015 | candidiasis, invasive | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 4 | NCT01968395 | Sep 2013 → Aug 2014 | infectious disease, liver disorder | Erasme University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01499433 | Jan 2012 → Sep 2014 | chronic obstructive pulmonary disease, invasive aspergillosis | The First Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01062165 | Feb → Dec 2010 | fungal infectious disease, obesity disorder | Texas Tech University Health Sciences Center | Completed | No outcome recorded |
| Phase 4 | NCT00334412 | Mar 2004 → May 2006 | invasive aspergillosis | Gilead Sciences | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT02603575 | Nov 2015 → Dec 2020 | pneumocystosis | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| — | NCT02596984 | Mar 2015 → May 2018 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| — | NCT02510053 | Jul 2014 → Jun 2016 | fungal infectious disease | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT00020527 | Mar 2001 → Jun 2003 | infectious disease, kidney cancer, leukemia, lymphoma +3 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00005921 | — | HIV infectious disease, esophageal candidiasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Comparator or background therapy15 trials | ||||||
| Phase 1/2 | NCT02856178 Background | Apr 2017 | acute myeloid leukemia, invasive aspergillosis | F2G Ltd | Withdrawn | No outcome recorded |
| Phase 2 | NCT06194201 Comparator | Apr 2024 → Nov 2025 | candidiasis | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02734862 Comparator | Jul 2016 → Jun 2019 | candidemia | Cidara Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05421858 Comparator | Dec 2024 → Jan 2028 expected | candidemia | Basilea Pharmaceutica | Recruiting | No outcome recorded |
| Phase 3 | NCT05178862 Background | Aug 2022 → Nov 2025 | candidemia | Scynexis, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03667690 Comparator | Oct 2018 → Oct 2021 | candidemia | Cidara Therapeutics Inc. | Completed | Met primary |
| Phase 3 | NCT01058174 Comparator | Dec 2009 → May 2012 | fungal infectious disease | Astellas Pharma Inc | Completed | Met primary |
| Phase 3 | NCT00413218 Comparator | Mar 2007 → Mar 2015 | candidemia | Astellas Pharma Inc | Completed | Missed primary |
| Phase 3 | NCT00105144 Comparator | Sep 2004 → Apr 2006 | candidemia | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00665639 Comparator | Jun → Dec 2004 | oral candidiasis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT04728971 Comparator | Oct 2022 → Oct 2025 | — | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT02895529 Comparator | Nov 2016 → May 2018 | hematopoietic and lymphoid cell neoplasm | Xian-Janssen Pharmaceutical Ltd. | Terminated | No outcome recorded |
| Phase 4 | NCT00839540 Comparator | Dec 2008 → May 2010 | candidemia | Gary E. Stein, Pharm.D. | Completed | No outcome recorded |
| Phase 4 | NCT00520234 Comparator | Aug 2007 → Mar 2010 | candidiasis, invasive | Mycoses Study Group | Completed | No outcome recorded |
| — | NCT00982540 Comparator | Feb 2010 → Nov 2013 | fusariosis, invasive aspergillosis | Federal University of Rio de Janeiro | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-06-11 | Scynexis, Inc. | Results SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018 scynexis.com ↗
These results show that minimum inhibitory concentrations (MIC) for SCY-078 and caspofungin were lower in Sabouraud dextrose broth than in RPMI, a standard medium employed for this determination. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-06-11 | Scynexis, Inc. | SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018 scynexis.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 67 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Caspofungin | “Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants.” PMID 19841031 ↗ Oct 200955“The patients included in this protocol require routine treatment with caspofungin or micafungin.” NCT02805049 ↗ “Caspofungin: 70 mg on the first day of therapy, followed by 50 mg q.d.” NCT01501708 ↗ “Caspofungin” NCT05178862 ↗ |
| Known as | Cancidas | “Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit” NCT02510053 ↗2“Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection” NCT00806351 ↗ “Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Patients With Candida Deep Tissue Infection” NCT00805740 ↗ |
| Known as | Cancidas (previously caspofungin msd) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | Caspofungin (as acetate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | Caspofungin accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | caspofungin acetate | “Giving caspofungin acetate may be effective in preventing or controlling fever and neutropenia caused by chemotherapy or bone marrow transplantation.” NCT00020527 ↗13“Subjects receive Caspofungin acetate 50mg/day IV for 28 days.” NCT00095316 ↗ “MK0991, caspofungin acetate/Duration of Treatment: variable” NCT00083343 ↗ “MK0991, caspofungin acetate / Duration of Treatment:” NCT00548080 ↗ “caspofungin acetate (MK0991)” NCT00717860 ↗ “MK0991, caspofungin acetate” NCT00076869 ↗ “Drug: Caspofungin acetate” NCT01045798 ↗ |
| Known as | Caspofungin Acetate for Injection | “Drug: Caspofungin Acetate for Injection” NCT06194201 ↗ |
| Known as | Caspofungin diacetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | Caspofungina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | Caspofungine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1630575 ↗ |
| Known as | L-743,872 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005921 ↗ |
| Known as | MK0991 | “MK0991, caspofungin acetate/Duration of Treatment: variable” NCT00083343 ↗3“MK0991, caspofungin acetate / Duration of Treatment:” NCT00548080 ↗ “caspofungin acetate (MK0991)” NCT00717860 ↗ |
| Action | Inhibit | “glucan synthase inhibitor” NCT00095316 ↗ |
| Modality | Other / unclassified | “echinocandin” NCT00839540 ↗ |
| Route | Intravenous | “administered intravenously by a peripheral line” NCT00005920 ↗ |